Cancer treatment for those nearing death has become increasingly aggressive over time despite evidence that less aggressive approaches are associated with better quality of life and sometimes longer survival. Chemotherapy administration in the last 14 days of life is one of the proposed benchmarks for quality of cancer care. The purpose of our study is to evaluate factors associated with aggressive cancer treatment in patients who died within 2 weeks of receiving chemotherapy.
Methods:
This retrospective cohort study evaluated adult patients who died between 1 February 2018 and 1 March 2019 after receiving cancer treatment in the preceding 14 days at the Prisma Health Cancer Institute. This project was approved by our institutional review board. Data was obtained by review of electronic medical records and analyzed using commercial software.
Results:
We identified 92 patients who met inclusion criteria for the study. Of those who were staged, 57% had metastatic disease. A majority received treatments with only palliative intent (54%). These patients overwhelmingly died in the hospital (62%). Few had documented advanced directives (28%) or dedicated palliative care for longer than 1 week (28%). Overall, this cohort reflects a rate of 11.7% of patients who received cancer treatment during the study time period.
Significance of Results:
Patients receiving aggressive cancer treatment at the end of life elucidate significant gaps in quality cancer care, particularly the early involvement of dedicated palliative care. Systematic review helped identify multiple gaps and assisted in implementing interventions to improve this outcome.
ClarkeGJohnstonSCorriePKuhnIBarclayS.Withdrawal of anticancer therapy in advanced disease: a systematic literature review. BMC cancer. 2015;15(893):892. https://www.ncbi.nlm.nih.gov/pubmed/26559912. doi:10.1186/s12885-015-1862-0
2.
TemelJSGreerJAMuzikanskyA, et al.Early palliative care for patients with metastatic non–small-cell lung cancer. New England Journal of Medicine. 2010;363(8):733–742. https://dx-doi-org.web.bisu.edu.cn/10.1056/NEJMoa1000678. doi:10.1056/NEJMoa1000678
ZdenkowskiNCavenaghJKuYCBisqueraABonaventuraA.Administration of chemotherapy with palliative intent in the last 30 days of life: the balance between palliation and chemotherapy. Internal Medicine Journal. 2013;43(11):1191–1198. https://onlinelibrary-wiley-com-443.web.bisu.edu.cn/doi/abs/10.1111/imj.12245. doi:10.1111/imj.12245
WrightAAZhangBKeatingNLWeeksJCPrigersonHG. Associations between palliative chemotherapy and adult cancer patients’ end of life care and place of death: prospective cohort study. BMJ: British Med J. 2014;348(mar04 4):g1219. https://dx-doi-org.web.bisu.edu.cn/10.1136/bmj.g1219. doi:10.1136/bmj.g1219
7.
ASCO. QOPI 2020 reporting tracks. Am Soc Clin Oncol. 2020:1–14.
8.
BehlDJatoiA. What do oncologists say about chemotherapy at the very end of life? Results from a semiqualitative survey. J Palliative Med. 2010;13(7):831–835. https://www.ncbi.nlm.nih.gov/pubmed/20636153. doi:10.1089/jpm.2009.0414
SchneiterMKMohanaKCrispensMAPrescottLSBrownAJ. The earlier the better: The role of palliative care consultation on aggressive end of life care, hospice utilization, and advance care planning documentation among gynecologic oncology patients. Support Care Cancer. 2019;27(5):1927–1934.
11.
FinnLGreenARMalhotraS.Oncology and palliative medicine: providing comprehensive care for patients with cancer. Ochsner J. 2017;17(4):393–397. https://www.ncbi.nlm.nih.gov/pubmed/29230124
12.
MullenMMDivineLMPorcelliBP, et al.The effect of a multidisciplinary palliative care initiative on end of life care in gynecologic oncology patients. Gynecol Oncol. 2017;147(2):460–464.
13.
FerrellBRTemelJSTeminS, et al.Integration of palliative care into standard oncology care: American society of clinical oncology clinical practice guideline update. J Clinical Oncol. 2017;35(1):96–112. https://search.datacite.org/works/10.1200/jco.2016.70.1474. doi:10.1200/jco.2016.70.1474
EarleCCNevilleBALandrumMBAyanianJZBlockSDWeeksJC. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol. 2004;22(2):315–321.
16.
KacenLMadjarIDenhamJAcklandSAriadS. Patients deciding to forgo or stop active treatment for cancer. Eur J Pall Car. 2005;12(3):113–116.
17.
TheAMHakTKoëterGvan der WalG. Collusion in doctor-patient communication about imminent death: an ethnographic study. JAMA, J Am Med Assoc. 2001;285(5):518.
18.
Lee CharSJEvansLRMalvarGLWhiteDB. A randomized trial of two methods to disclose prognosis to surrogate decision makers in intensive care units. Am J Respirat Crit Care Med. 2010;182(7):905–909. https://www.ncbi.nlm.nih.gov/pubmed/20538959. doi:10.1164/rccm.201002-0262OC
19.
SlevinMLStubbsLPlantHJ, et al.Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. British Medical Journal. 1990;300(6737):1458–1460. https://dx-doi-org.web.bisu.edu.cn/10.1136/bmj.300.6737.1458. doi:10.1136/bmj.300.6737.1458
20.
McQuellonRPMussHBHoffmanSLRussellGCravenBYellenSB. Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer. J Clin Oncol. 1995;13(4):858–868.
21.
EpsteinASPrigersonHGO’ReillyEMMaciejewskiPK. Discussions of life expectancy and changes in illness understanding in patients with advanced cancer. J Clin Oncol Offic J Am Soc Clin Oncol. 2016;34(20):2398–2403. https://www.ncbi.nlm.nih.gov/pubmed/27217454. doi:10.1200/JCO.2015.63.6696
22.
HarringtonSSmithT. The role of chemotherapy at the end of life: “When is enough, enough?”JAMA. 2008;299(22):2667–2678.
23.
SarenmalmEKThorén-JönssonA-LGaston-JohanssonFOhlénJ. Making sense of living under the shadow of death: adjusting to a recurrent breast cancer illness. . Qual Health Res. 2009;19(8):116–130.
24.
WeeksJCCatalanoPJCroninA, et al.Patients’ expectations about effects of chemotherapy for advanced cancer. N Engl J Med. 2012;367(17):1616–1625. https://dx-doi-org.web.bisu.edu.cn/10.1056/NEJMoa1204410. doi:10.1056/NEJMoa1204410
25.
SmithTJHillnerBE. Explaining marginal benefits to patients, when “marginal” means additional but not necessarily small. Clin Cancer Res. 2010;16:5981–5986.
26.
BackALArnoldRMTulskyJA. Mastering communication with seriously ill patients: balancing honesty with empathy and hope. 2009.
27.
BackALArnoldRM. Discussing prognosis: “how much do you want to know?”—Talking to patients who do not want information or who are ambivalent. J Clin Oncol. 2006;24(25):4214–4217.
28.
PeppercornJMThomasJSPaulRH, et al.American society of clinical oncology statement: toward individualized care for patients with advanced cancer. Journal of Clinical Oncology. 2011;29(6):755–760. http://jco.ascopubs.org/content/29/6/755.abstract. doi:10.1200/JCO.2010.33.1744
29.
BackALMichaelsenKAlexanderSHopleyEEdwardsKArnoldRM. How oncology fellows discuss transitions in goals of care: a snapshot of approaches used prior to training. Journal of Palliative Medicine. 2010;13(4):395–400. https://www.ncbi.nlm.nih.gov/pubmed/20307195. doi:10.1089/jpm.2009.0249
30.
RobinsonKSuttonSVon GuntenCF, et al.Assessment of the education for physicians on end-of-life care (EPEC) project. J Palliat Med. 2004;7(5):637–645.
31.
McCulloughLMcKinlayEBarthowCMossCWiseD. A model of treatment decision making when patients have advanced cancer: how do cancer treatment doctors and nurses contribute to the process?Eur J Cancer Care (Engl). 2010;19(4):482–491.
32.
MeekerMA.Responsive care management: family decision makers in advanced cancer. J Clin Ethics. 2011;22(2):107–122.
33.
ReinkeLEngelbergRShannonS, et al.Transitions regarding palliative and end-of-life care in severe chronic obstructive pulmonary disease or advanced cancer: themes identified by patients, families, and clinicians. J Palliat Med. 2008;11(4):601–609.
34.
SchildmannJTanJSallochSVollmanJ.Well, I think there is great variation: a qualitative study of oncologists’ experiences and views regarding medical criteria and other factors relevant to treatment decisions in advanced cancer. The Oncol. 2013;18(1):90–96.
35.
AdelsonKParisJHortonJR, et al.Standardized criteria for palliative care consultation on a solid tumor oncology service reduces downstream health care use. Journal of Oncology Practice. 2017;13(5):e431–e440. https://search.datacite.org/works/10.1200/jop.2016.016808. doi:10.1200/jop.2016.016808
